Advances in cancer detection technology predict global market for MRD testing to reach $6.67 billion by 2033

Global MRD testing market

DUBLIN, March 19, 2024 (GLOBE NEWSWIRE) — “MRD Testing Market – Global and Regional Analysis: Focus on Technology, Target Detection, End User and Regional Analysis – Analysis and Forecast, 2023-2033 ” report added. ResearchAndMarkets.com Recruitment.

A comprehensive market analysis for minimal residual disease (MRD) testing, including global and regional insights, technology focus, target detection, and diverse end-user involvement, was recently published. This report provides detailed forecasts from 2023 to 2033 and explores the pivotal role of MRD testing in improving cancer treatment outcomes and patient survival.

The MRD testing market has been identified to be valued at a significant $1.67 billion in 2023 and is projected to rise to $6.67 billion by 2033, at a CAGR of 14.81% is. Key growth drivers include expansion of medical insurance coverage for MRD testing, increased performance of solid tumor diagnostics, and increased consumer awareness.

Market life cycle stages This area of ​​healthcare has experienced rapid growth driven by the demand for accurate and sensitive technology that can effectively monitor and manage the care of cancer patients. This report puts technologies such as PCR, NGS, and flow cytometry at the forefront, highlighting both current trends and the essential future of MRD testing.

Impact on industry

• Flow cytometry: With innovative techniques that improve detection sensitivity, it continues to dominate as the leading technology for MRD testing.

• Target detection: According to 2022 data, the leukemia segment is dominant in MRD testing, with significant implications for personalized cancer treatment.

• End-user: Hospitals and specialty clinics are leading the way in providing MRD testing services, adapting to the increasing influx of advanced diagnostic requirements.

regional analysis A detailed regional outlook reveals that China maintains the highest growth within the Asia-Pacific region, despite economic disparities impacting MRD testing adoption rates. The report provides a comprehensive breakdown of various regional indicators and points to the potential for growth with the development of a more accessible and harmonized regulatory framework.

recent trends The report highlights recent strategic advances in the MRD testing space, including Quest Diagnostics' acquisition of Haystack Oncology and Integrated DNA Technologies' launch of an innovative research panel. These moves mean improved test accuracy and increased market diversity.

Demand – Drivers and Limitations

story continues

• Drivers: The report suggests that rapidly increasing cancer rates, Medicare expansion, and increased consumer awareness are major drivers of MRD testing adoption.

• Challenges: High cost and possible early risk of progression due to misleading negative MRD results have been identified as the main challenges.

• Opportunities: Advances in technology and an increase in clinical trials offer unprecedented opportunities for market expansion.

Strategic contributions by various key market players, such as forming partnerships and collaborations, are crucial in enhancing the competitive landscape of the MRD testing market. This report offers a comprehensive analysis of such activities with the aim of directing readers to potential profit areas within the market.

The report is methodologically rigorous, leveraging secondary and primary research to verify market data, ensuring a reliable source of market insights, benchmarks, and competitive strategies. This analysis covers a wide range of major companies, including both public and private entities, providing a holistic view of their current market positions and potential strategic growth areas.

For those seeking to understand the intricacies of the MRD testing market, this newly added publication serves as an essential resource for strategic decision-making and market understanding.

Market trend

• market drivers

  • The advent of MRD testing and consumer awareness

  • Increase in cancer cases requiring MRD testing

  • Increased control of solid tumor diagnostics in the MRD testing ecosystem

  • Expanding Medicare coverage of MRD testing

• market challenges

• market opportunity

key attributes

Companies mentioned

• adaptive biotechnology

• Arup Research Institute

• Bio-Rad Laboratories, Inc.

• Sergentis BV

• F. Hoffman La Roche Co., Ltd.

• Guardant Health Co., Ltd.

• Invivoscribe Co., Ltd.

• Laboratory Corporation of America Holdings

• Mission Bio Co., Ltd.

• Icon Co., Ltd.

• Natera Co., Ltd.

• Neo Genomics Institute Co., Ltd.

• Opco Health Co., Ltd.

• Quest Diagnostics Incorporated

• Sysmex Corporation

For more information on this report, please visit https://www.researchandmarkets.com/r/ovbq41.

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source of international market research reports and market data. We provide the latest data on international and regional markets, key industries, top companies, new products and latest trends.

attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900